Research Topics
Genomes and Genes | Lars Gunnar LarssonSummaryAffiliation: Karolinska Institutet Country: Sweden Publications
| Collaborators
|
Detail Information
Publications
The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapyLars Gunnar Larsson
Department of Microbiology, Tumor and Cell Biology MTC, Karolinska Institutet, Box 280, 171 77 Stockholm, Sweden
Exp Cell Res 316:1429-37. 2010....
Oncogene- and tumor suppressor gene-mediated suppression of cellular senescenceLars Gunnar Larsson
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, SE 171 77 Stockholm, Sweden
Semin Cancer Biol 21:367-76. 2011..This can hopefully form the basis for a "pro-senescence therapy" strategy to combat cancer in the future...
Tipping the balance: Cdk2 enables Myc to suppress senescencePer Hydbring
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
Cancer Res 70:6687-91. 2010....
Cdk2: a key regulator of the senescence control function of MycPer Hydbring
Department of Microbiology, Tumor and Cell Biology MTC, Karolinska Institutet, 171 77 Stockholm, Sweden
Aging (Albany NY) 2:244-50. 2010..Importantly, selective pharmacological inhibition of Cdk2 forced Myc/Ras expressing cells into cellular senescence, highlighting this kinase as a potential therapeutic target for treatment of tumors driven by Myc or Ras...
Myc is required for activation of the ATM-dependent checkpoints in response to DNA damageLina Guerra
Department of Cell Biology, Karolinska Institutet, Stockholm, Sweden
PLoS ONE 5:e8924. 2010..In response to genotoxic agents, cells overexpressing MYC undergo apoptosis. However, the MYC-regulated effectors acting upstream of the mitochondrial apoptotic pathway are still unknown...
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformationPer Hydbring
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE 171 77 Stockholm, Sweden
Proc Natl Acad Sci U S A 107:58-63. 2010..Finally, our findings highlight that pharmacological inhibition of Cdk2 activity is a potential therapeutical principle for cancer therapy, in particular for tumors with activated Myc or Ras...
Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemiaKari Högstrand
Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
PLoS ONE 7:e31366. 2012..In conclusion, our findings provide direct evidence that BCL-X(L) and BCL-2 but not FLIP(L) acts in synergy with MYC to drive AML development...
